Evidence map›Paper›PMID 31818965›Full record

ArticleInfection and immunity2020

Bypassing Phase Variation of Lipooligosaccharide (LOS): Using Heptose 1 Glycan Mutants To Establish Widespread Efficacy of Gonococcal Anti-LOS Monoclonal Antibody 2C7.

Srinjoy Chakraborti, Sunita Gulati, Bo Zheng, Frank J Beurskens, Janine Schuurman, Peter A Rice, Sanjay Ram

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection and immunity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Frontiers in immunology · 2024
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Srinjoy ChakrabortiDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Sunita GulatiDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Bo ZhengDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Frank J BeurskensDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Janine SchuurmanGenmab, Utrecht, The Netherlands.
Peter A RiceDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Sanjay RamDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA sanjay.ram@umassmed.edu.
University of Massachusetts Chan Medical School · USGenmab (Netherlands) · NL

Funding

Novel immunotherapeutics against multidrug-resistant Neisseria gonorrhoeaR01AI132296 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAM, SANJAY, RICE, PETER A. · 2017 to 2021
$5.5M
A novel vaccine against multidrug-resistant gonorrheaR01AI141181 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAM, SANJAY, RICE, PETER A. · 2019 to 2023
$4.3M
Immune defenses against Neisseria gonorrhoeaeR01AI114790 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAM, SANJAY, RICE, PETER A. · 2015 to 2019
$3.1M
Vaccines and Immunotherapeutics against gonorrhea in the contex of Chlamydia coU01AI118161 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAM, SANJAY · 2014 to 2017
$2.0M
Lipooligosaccharide mimitope vaccines against Neisseria gonorrhoeaeR01AI114710 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI GULATI, SUNITA, RICE, PETER A. · 2015 to 2018
$1.8M
NIAID NIH HHS R01 AI114710NIAID NIH HHS R01 AI114790NIAID NIH HHS R01 AI132296NIAID NIH HHS R01 AI141181NIAID NIH HHS U01 AI118161
6 · The paper itself

Abstract

The sialylatable lacto-

Indexed as

AnimalsAntibodies, BacterialAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedDisease Models, AnimalFemaleGonorrheaLipopolysaccharidesMice, Inbred BALB CNeisseria gonorrhoeaeTreatment OutcomeVaginaAntibodies, BacterialAntibodies, MonoclonalAntibodies, Monoclonal, Humanizedlipid-linked oligosaccharidesLipopolysaccharidesgonorrhealipooligosaccharidemonoclonal antibodiesNeisseria gonorrhoeae

Identifiers

PMID31818965
PMCPMC6977115
OpenAlexW2995969199

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.